Biogen Inc.
Location
Massachusetts
Founded
1978-02-28
Website
Risk Signals
2647 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Pharmaceutical Preparations, Biological Products, Except Diagnostic Substances, Commercial Physical and Biological Research), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Biogen Inc.
Live alerts from global media, monitored by Business Radar
2025-03-16 (marketbeat.com)
Scandinavian Enskilda Bank AB Publ Sells 14,072 Shares of Biogen Inc. (Nasdaq: BIIB)
Skandinaviska Enskilda Banken AB publ decreased its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 24.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 43,047 shares of the biotechnology
Read more
2025-01-29 (tipranks.com)
M&A News: Sage Rejects Biogen’s $469M Takeover Bid over Valuation Concerns - TipRanks.com
Biopharmaceutical company Sage Therapeutics ($SAGE) has rejected Biogen’s ($BIIB) $469 million takeover offer, citing valuation concerns in the proposal. Biogen, wh...
Read more
2025-01-16 (marketbeat.com)
Czech National Bank Acquires 1,923 Shares of Biogen Inc. (NASDAQ:BIIB)
Czech National Bank boosted its position in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 6.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 31,595 shares of the biotechnology company's stock after acquiring
Read more
2025-01-13 (defenseworld.net)
GAMMA Investing LLC Decreases Position in Biogen Inc. (NASDAQ:BIIB) -
Read GAMMA Investing LLC Decreases Position in Biogen Inc. (NASDAQ:BIIB) at Defense World
Read more
2024-12-30 (trefis.com)
Biogen (BIIB) Valuation: BIIB Stock Looks Appropriately Priced With $150 Price Estimate |
. Debug Trail. Untitled Section. Valuation Derived From: [1] Price To Sales Ratio (P/S) Based Estimate. [1] Price To Sales Ratio (P/S) Based Estimate: $null. [i] Estimating Biogen Price To Sales Ratio Of 0.0. What Price to Sales Ratio Makes Sense? [ii] Estimating Biogen Revenue Per Share (FY2023E) Of $null. What Revenue Growth Makes Sense? [2] Price To Earnings Ratio (P/E) Based Estimate: $0.0 [i] BIIB Price To Earnings Ratio (0.0) x [ii]FY 2024E Earnings Per Share ($null). [i] Estimating Biogen Price To Earnings Ratio Of 0.0. What Price to Earnings Ratio Makes Sense? [ii] Estimating Biogen Earnings Per Share (FY2024E) of $null. Net Income (FY2024E) = Revenue (FY2024E) x Net Margin (FY2024E). Making Sense of Biogen Valuation. More from Trefis. Biogen Insights. Invest in Market-Beating Trefis Portfolios.
Read more
2024-12-15 (marketbeat.com)
Quantinno Capital Management LP Lowers Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Quantinno Capital Management LP lowered its stake in Biogen Inc. (NASDAQ:BIIB - Free Report) by 62.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,069 shares of the biotechnology company's stock after selling 5,172
Read more
2024-12-13 (marketbeat.com)
Inspire Trust Co. N.A. Grows Stock Holdings in Biogen Inc. (NASDAQ:BIIB)
Inspire Trust Co. N.A. grew its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 58.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 10,900 shares of the biotechnology company's stock after buying an additional 4,0
Read more
2024-12-02 (wallstreet-online.de)
Bargain for 2025, a buy rating, attractive kgvs and room for improvement, these shares have in common 02122024
Although the stock market is currently at historically high valuation levels, experts continue to identify attractive buying opportunities...
Read more
2024-12-01 (marketbeat.com)
zurcher kantonalbank zurich cantonalbank sells 3707 shares of biogen inc nasdaqbiib
Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 5.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 69,649 shares of the biotechnology company's stock after
Read more